Enanta Pharmaceuticals (ENTA) Upgraded to B- by TheStreet
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by research analysts at TheStreet from a “c+” rating to a “b-” rating in a note issued to investors on Wednesday.
A number of other equities research analysts have also issued reports on the stock. Royal Bank of Canada upped their target price on shares of Enanta Pharmaceuticals from $54.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. JMP Securities upped their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Finally, Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $46.25.
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at $53.95 on Wednesday. Enanta Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $54.98. The stock has a market cap of $1,032.42, a price-to-earnings ratio of 61.34 and a beta of 0.64.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million for the quarter, compared to analysts’ expectations of $73.80 million. During the same period in the previous year, the company earned ($0.09) EPS. Enanta Pharmaceuticals’s quarterly revenue was up 491.3% compared to the same quarter last year. analysts predict that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. GAM Holding AG purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $108,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 110 shares during the period. SG Americas Securities LLC grew its holdings in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares during the period. BNP Paribas Arbitrage SA grew its holdings in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares during the period. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $205,000. 66.97% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Enanta Pharmaceuticals (ENTA) Upgraded to B- by TheStreet” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/enanta-pharmaceuticals-enta-upgraded-to-b-by-thestreet/1765291.html.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.